InterCure Ltd. (INCR)

IL — Healthcare Sector
Peers: CRDL  ASRT  NTRB  STTK  HYFT  IFRX  ACET  WHWK  EDAP 

Automate Your Wheel Strategy on INCR

With Tiblio's Option Bot, you can configure your own wheel strategy including INCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol INCR
  • Rev/Share 4.0074
  • Book/Share 9.0557
  • PB 0.5342
  • Debt/Equity 0.5325
  • CurrentRatio 1.7279
  • ROIC -0.1414

 

  • MktCap 263262702.5355
  • FreeCF/Share 0.0
  • PFCF 0.0
  • PE -3.0955
  • Debt/Assets 0.2772
  • DivYield 0
  • ROE -0.1639

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
INCR
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel

Read More
image for news InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
INCR
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel

Read More
image for news InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
INCR
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

Acquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies

Read More
image for news InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands

About InterCure Ltd. (INCR)

  • IPO Date 2019-01-28
  • Website https://www.intercure.co
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Alexander Rabinovich
  • Employees 320
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.